Stay updated on Lebrikizumab Long-term Safety Efficacy AD Clinical Trial
Sign up to get notified when there's something new on the Lebrikizumab Long-term Safety Efficacy AD Clinical Trial page.

Latest updates to the Lebrikizumab Long-term Safety Efficacy AD Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedRevision label updated from v3.3.1 to v3.3.2; no impact on the study details or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check22 days agoChange DetectedPublication notes now state that PubMed feeds are automatically filled and add Revision: v3.3.1; the previous PubMed-based description has been removed (Revision: v3.2.0).SummaryDifference0.4%

- Check30 days agoChange DetectedAdded a new Lebrikizumab long-term data publication to the Publications section and removed the NIH funding-status notice.SummaryDifference0.1%

- Check37 days agoChange DetectedThe page adds Open-Label Extension Addendum arms for Lebrikizumab Q4W and Q8W (up to 32 weeks) and new primary/secondary outcomes (AE discontinuation, IGA 0/1 at Week 100, EASI-75 at Week 100), plus updated study protocol documents.SummaryDifference0.4%

- Check44 days agoChange DetectedThere are no significant changes detected on the page; the study details and layout appear unchanged from the previous view.SummaryDifference0.1%

- Check73 days agoChange DetectedMajor change: update to v3.2.0 with a prominent notice about government funding status and operating status; removal of v3.1.0. If any time-sensitive content is shown elsewhere, it may now reflect the new version and funding status.SummaryDifference1%

Stay in the know with updates to Lebrikizumab Long-term Safety Efficacy AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lebrikizumab Long-term Safety Efficacy AD Clinical Trial page.